Why This Piece Exists
Fertility is the most emotionally loaded topic in women's health. When you're struggling to conceive, you will try almost anything — and an entire industry exists to exploit that willingness. Peptides have entered the fertility conversation from multiple directions: some legitimate (clinical trials at major research hospitals), some questionable (vendor-promoted "fertility stacks"), and some dangerous (unregulated self-experimentation during conception attempts).
This article sorts through what's real. Every claim is tied to its evidence level. Where evidence is absent, that's stated plainly. If you're navigating fertility challenges, the single most important sentence in this article is this one: work with a reproductive endocrinologist, not a peptide vendor.
The Three Real Connections
What it is: Kisspeptin-54, administered as a single subcutaneous injection, triggering final oocyte maturation in IVF — replacing the standard hCG trigger that carries risk of ovarian hyperstimulation syndrome (OHSS).
What the evidence shows: Multiple clinical trials, primarily from the Dhillo group at Imperial College London, have demonstrated that kisspeptin-54 successfully triggers egg maturation with zero cases of clinically significant OHSS — even in women with PMOS, who are at the highest risk. Pregnancy rates were comparable to standard protocols in the studies completed so far.
What this means for you: If you have PMOS and are considering IVF, kisspeptin represents a genuine potential advance in making the process safer. It is not yet available through fertility clinics — it remains in clinical trials. The research-grade kisspeptin-10 sold by peptide vendors is a truncated fragment, not the kisspeptin-54 used in trials. This is a development to track, not a product to buy.
The limitation: Larger Phase 3 trials are needed to confirm pregnancy-rate equivalence at scale before kisspeptin can replace hCG as standard of care.
What it is: The "Ozempic baby" phenomenon — unexpected pregnancies in women taking GLP-1 receptor agonists (semaglutide, tirzepatide), sometimes after years of diagnosed infertility.
What the evidence shows: This is not a single study — it's a pattern reported across clinics, patient communities, and pharmacovigilance databases. The likely mechanism involves two pathways: (1) improved insulin sensitivity restoring ovulatory function in women with PMOS-related anovulation, and (2) reduced efficacy of oral contraceptives due to slowed gastric emptying and altered gut absorption.
What this means for you: If you have PMOS or insulin-resistant anovulation, GLP-1 agonists may improve your ovulatory function as a secondary effect of metabolic improvement. This is not the same as being studied and approved for fertility — it's a clinically observed side effect. If you're on a GLP-1 and not trying to conceive, discuss backup contraception with your provider. If you are trying to conceive, discuss the GLP-1 washout period (semaglutide: 2 months before planned pregnancy; tirzepatide: 1 month).
The limitation: The fertility effect is observational, not from controlled fertility trials. Confounders (weight loss itself improving fertility, selection bias in reporting) make it hard to isolate the GLP-1-specific effect. Animal studies showed developmental concerns at high doses, hence the washout recommendations.
What it is: BPC-157 (Body Protection Compound) is a gastric pentadecapeptide with anti-inflammatory and tissue-repair properties. It has generated significant interest in the endometriosis community because endometriosis involves inflammatory tissue growth, adhesion formation, and chronic pelvic inflammation — all processes that BPC-157's mechanisms theoretically address.
What the evidence shows: Dozens of animal studies demonstrate BPC-157's tissue-protective and anti-inflammatory effects across multiple organ systems. A pilot study in interstitial cystitis (12 women) showed striking results. However: there are zero human clinical trials studying BPC-157 for endometriosis, fertility, or any reproductive condition. The connection is entirely mechanistic reasoning — "this peptide repairs tissue and reduces inflammation" → "endometriosis is a tissue and inflammation problem" → "therefore it should help." That logic is plausible but unproven.
What this means for you: If you have endometriosis and are exploring complementary approaches, BPC-157's anti-inflammatory properties are a reasonable area of interest. But understand that you are the experiment — there is no dosing data, no safety data, and no efficacy data for this specific application. Do not use BPC-157 as a substitute for evidence-based endometriosis treatment (hormonal therapy, surgery, or ART for fertility).
The Hype: What Doesn't Have Evidence
"Fertility peptide stacks" sold by research vendors — typically combinations of BPC-157, CJC-1295/Ipamorelin (a growth hormone secretagogue), and various other peptides — marketed as "optimizing reproductive health" or "supporting egg quality." There is no published clinical data supporting any multi-peptide stack for fertility. The claims are marketing extrapolations from unrelated research. These products are not tested for reproductive safety.
Specific claims that circulate on social media and peptide forums, and their evidence status:
- "GH secretagogues improve egg quality." Growth hormone supplementation has been studied in IVF (as an adjunct for poor responders), with mixed results. GH secretagogue peptides (CJC-1295, Ipamorelin, MK-677) are not the same as pharmaceutical GH. No study has examined whether GH secretagogue peptides improve egg quality. Extrapolating from GH supplementation trials to secretagogue peptides is scientifically invalid.
- "TB-500 heals the uterine lining." TB-500 (Thymosin Beta-4) promotes tissue repair and angiogenesis in wound-healing studies (primarily tendon, cardiac, and corneal tissue). No study has examined its effects on endometrial tissue. "Tissue repair" does not automatically apply to all tissues equally.
- "NAD+ improves ovarian reserve." There is mouse-model research suggesting NAD+ precursors (NMN, NR) may improve oocyte quality in aged mice. These are preclinical animal studies. No human trial has demonstrated that NAD+ supplementation — let alone injectable NAD+ — improves ovarian reserve, egg quality, or fertility outcomes in women.
- "Epithalon extends reproductive lifespan." Epithalon (epitalon) is a tetrapeptide studied for telomere support, primarily by a single Russian research group. No fertility-specific data exists in any species. The claim is pure speculation.
The Dangerous Middle Ground
The most concerning scenario is not outright scams — it's well-intentioned self-experimentation during the conception window.
Research-grade peptides from online vendors are manufactured for laboratory use, not human consumption. They are not tested for reproductive safety, not tested for teratogenicity (birth defect potential), not tested for effects on embryonic development, and not manufactured under pharmaceutical GMP standards. Using them during conception attempts introduces unknown risks to both the mother and the potential embryo.
The GLP-1 washout guidance exists for a reason. Even FDA-approved, pharmaceutical-grade, extensively-studied GLP-1 agonists carry precautionary washout periods before pregnancy (semaglutide: 2 months; tirzepatide: 1 month) because animal studies at high doses raised developmental concerns. If drugs with billions of dollars of safety data carry this caution, research-grade peptides with no reproductive safety data at all should carry far more.
This is not a general warning against peptides. It is a specific warning about timing. If you are actively trying to conceive or might become pregnant, the risk-benefit calculation for unregulated peptides is fundamentally different from using them at any other time in your life.
What a Reproductive Endocrinologist Can Actually Do
The evidence-based fertility toolkit in 2026 is broader than many women realize:
- Letrozole and Clomid for ovulation induction — first-line for anovulatory infertility, including PMOS.
- Metformin for insulin-resistant PMOS — improves ovulatory function and may be combined with letrozole.
- GLP-1 agonists (off-label) — some reproductive endocrinologists now prescribe semaglutide or tirzepatide for insulin-resistant PMOS before fertility treatment, with appropriate washout before conception.
- Gonadotropin therapy for controlled ovarian stimulation.
- IVF with ICSI — with improving trigger options (GnRH agonist trigger already reduces OHSS risk; kisspeptin may further improve safety once approved).
- Surgical management for endometriosis and anatomical factors.
- Egg freezing and embryo banking for fertility preservation.
A reproductive endocrinologist can diagnose the specific cause of your fertility challenge, select the appropriate intervention, monitor your response, and adjust. A peptide vendor cannot do any of these things.
The Bottom Line
The peptide-fertility connection is real in exactly two places: kisspeptin as a safer IVF trigger (clinical trial evidence, not yet available), and GLP-1 agonists improving ovulatory function through insulin sensitization (observational evidence, prescribed off-label by some reproductive endocrinologists). Everything else — fertility stacks, GH secretagogues for egg quality, TB-500 for the uterine lining, NAD+ for ovarian reserve — is marketing dressed up as science.
Fertility is too important and too time-sensitive to navigate with unregulated research chemicals and social media advice. Use the evidence. Work with a specialist. And if kisspeptin or another peptide-based fertility tool reaches approval, you'll read about it here first — with the same honest assessment of what the evidence actually shows.
Frequently Asked Questions
Can peptides help with fertility?
Some peptides have genuine connections to fertility. Kisspeptin-54 has clinical trial evidence as a safer IVF trigger. GLP-1 agonists have been observed to improve ovulatory function in women with insulin-resistant PMOS. However, no peptide is FDA-approved as a fertility treatment, and unregulated "fertility peptide stacks" have no clinical evidence.
What is the Ozempic baby phenomenon?
Unexpected pregnancies in women taking GLP-1 drugs, sometimes after years of infertility. The likely mechanism is improved insulin sensitivity restoring ovulation, plus potentially reduced oral contraceptive absorption from slowed gastric emptying.
Is it safe to use peptides while trying to conceive?
Most peptides have not been studied in pregnancy. GLP-1 agonists carry recommended washout periods (semaglutide: 2 months, tirzepatide: 1 month before planned pregnancy). Research-grade peptides have no pregnancy safety data. Always consult a reproductive endocrinologist before using any peptide while trying to conceive.
What about BPC-157 for endometriosis and fertility?
BPC-157's anti-inflammatory and tissue-repair properties have generated interest, but there are zero human clinical trials for endometriosis or fertility. The connection is mechanistic reasoning only — plausible but unproven.
Are "fertility peptide stacks" worth trying?
No. These unregulated combinations have zero clinical evidence for fertility. They are marketing extrapolations from unrelated research and are not tested for reproductive safety. Work with a reproductive endocrinologist, not a peptide vendor.